CSIMarket Company Name, Ticker, Suppliers, else..
 
Immunome Inc   (NASDAQ: IMNM)
 

Immunome Inc's Suppliers Performance

IMNM's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
IMNM Costs vs Sales of Suppliers Growth

• More on IMNM Suppliers






Immunome Inc's Comment on Supply Chain


The company sources raw materials, isotopes, and clinical trial materials for nonclinical and potential future clinical and commercial needs. It faces challenges in identifying and retaining suitable vendors, including contract research organizations (CROs) and clinical manufacturing organizations, due to the limited number of suppliers qualified to handle radioactive material. Sole-source vendor relationships present risks such as delays in obtaining diagnostic radiotracers, which have postponed the start of the Phase 1 clinical trial for IM-3050. Additionally, the short half-life of Lu-177 creates distribution challenges and increases expenses. The company is in the early stages of developing internal sales and marketing capabilities for commercialization and may rely on third parties for marketing and distribution; however, there is no assurance that such arrangements will be established on acceptable terms or at all.

Immunome Inc's Comment on Supply Chain


The company sources raw materials, isotopes, and clinical trial materials for nonclinical and potential future clinical and commercial needs. It faces challenges in identifying and retaining suitable vendors, including contract research organizations (CROs) and clinical manufacturing organizations, due to the limited number of suppliers qualified to handle radioactive material. Sole-source vendor relationships present risks such as delays in obtaining diagnostic radiotracers, which have postponed the start of the Phase 1 clinical trial for IM-3050. Additionally, the short half-life of Lu-177 creates distribution challenges and increases expenses. The company is in the early stages of developing internal sales and marketing capabilities for commercialization and may rely on third parties for marketing and distribution; however, there is no assurance that such arrangements will be established on acceptable terms or at all.







IMNM's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Immunome Inc 2,530.52 10.97 -254.32 177
SUBTOTAL 0.00 0.00 0.00 -


Sources: Immunome Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Immunome Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.